News Sentiment

EDSA sentiment intelligence

Edesa Biotech Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 7.01 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-6.5% over one week, +20.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

[EFFECT] Edesa Biotech, Inc. SEC Filing

Market Reaction

Price moving ahead of tone

70/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -6.5% Price reacting lower
Trend fit Trend active 20.9% over four weeks
Fair value 80.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 31
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 7
TradingView 6
TradingKey 4
GlobeNewswire 4
Moomoo 3
Stocktwits 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 13
Deals and strategy 4
Analyst action 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-51 of 51
Stock Titan Direct company coverage

Early trial data hint at fewer deaths from acute kidney injury

Edesa Biotech (Nasdaq: EDSA) reported positive exploratory data for its drug paridiprubart in 101 hospitalized patients with acute kidney injury (AKI) and respiratory distress. The data, drawn from prior Phase 2/3 ARDS studies, suggested a 32% relative reduction in 28-day mortali

Tone
Positive 73/100
Event
Market update
Published
05 Jun 2026 13:11
Source
Stock Titan
Stock Titan Direct company coverage

Exploratory AKI data show lower mortality with paridiprubart at Edesa (NASDAQ: EDSA)

Edesa Biotech (NASDAQ: EDSA) reported exploratory subgroup data indicating that its anti-TLR4 antibody, paridiprubart, may reduce mortality and major adverse kidney events (MAKE30) in critically ill patients with acute kidney injury (AKI) and respiratory distress. Pooled analyses

Tone
Positive 70/100
Event
Market update
Published
05 Jun 2026 13:11
Source
Stock Titan